company background image
HIKAL logo

Hikal NSEI:HIKAL Stock Report

Last Price

₹378.40

Market Cap

₹46.7b

7D

-8.4%

1Y

24.5%

Updated

20 Dec, 2024

Data

Company Financials +

Hikal Limited

NSEI:HIKAL Stock Report

Market Cap: ₹46.7b

HIKAL Stock Overview

Manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. More details

HIKAL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance1/6
Financial Health4/6
Dividends4/6

Rewards

Earnings are forecast to grow 49.2% per year

Risk Analysis

Interest payments are not well covered by earnings

Unstable dividend track record


My Notes

Capture your thoughts, links and company narrative

Hikal Limited Competitors

Aarti Pharmalabs

NSEI:AARTIPHARM

₹51.7b

Jeena Sikho Lifecare

NSEI:JSLL

₹56.2b

Morepen Laboratories

BSE:500288

₹43.8b

Gufic Biosciences

BSE:509079

₹43.3b

Price History & Performance

Summary of share price highs, lows and changes for Hikal
Historical stock prices
Current Share Price₹378.40
52 Week High₹464.75
52 Week Low₹260.30
Beta1.27
1 Month Change-3.72%
3 Month Change-2.10%
1 Year Change24.49%
3 Year Change-25.31%
5 Year Change236.36%
Change since IPO2,503.67%

Recent News & Updates

Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results

Nov 15
Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

Sep 13
Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

Recent updates

Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results

Nov 15
Hikal Limited (NSE:HIKAL) Analysts Are Pretty Bullish On The Stock After Recent Results

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

Sep 13
Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Sep 11
We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Hikal Limited's (NSE:HIKAL) Popularity With Investors Is Clear

Jun 12
Hikal Limited's (NSE:HIKAL) Popularity With Investors Is Clear

A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)

Jun 03
A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)

Is Hikal (NSE:HIKAL) Using Too Much Debt?

Mar 28
Is Hikal (NSE:HIKAL) Using Too Much Debt?

Hikal (NSE:HIKAL) Is Reducing Its Dividend To ₹0.60

Feb 07
Hikal (NSE:HIKAL) Is Reducing Its Dividend To ₹0.60

A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)

Dec 08
A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)

Increases to CEO Compensation Might Be Put On Hold For Now at Hikal Limited (NSE:HIKAL)

Sep 16
Increases to CEO Compensation Might Be Put On Hold For Now at Hikal Limited (NSE:HIKAL)

Calculating The Fair Value Of Hikal Limited (NSE:HIKAL)

Mar 18
Calculating The Fair Value Of Hikal Limited (NSE:HIKAL)

Hikal (NSE:HIKAL) Is Increasing Its Dividend To ₹1.20

Feb 16
Hikal (NSE:HIKAL) Is Increasing Its Dividend To ₹1.20

Is Hikal (NSE:HIKAL) Using Too Much Debt?

Jan 13
Is Hikal (NSE:HIKAL) Using Too Much Debt?

With EPS Growth And More, Hikal (NSE:HIKAL) Is Interesting

Jun 01
With EPS Growth And More, Hikal (NSE:HIKAL) Is Interesting

We Think Hikal (NSE:HIKAL) Can Stay On Top Of Its Debt

May 17
We Think Hikal (NSE:HIKAL) Can Stay On Top Of Its Debt

An Intrinsic Calculation For Hikal Limited (NSE:HIKAL) Suggests It's 25% Undervalued

Mar 23
An Intrinsic Calculation For Hikal Limited (NSE:HIKAL) Suggests It's 25% Undervalued

Does Hikal Limited (NSE:HIKAL) Have A Place In Your Dividend Portfolio?

Mar 10
Does Hikal Limited (NSE:HIKAL) Have A Place In Your Dividend Portfolio?

If You Like EPS Growth Then Check Out Hikal (NSE:HIKAL) Before It's Too Late

Feb 23
If You Like EPS Growth Then Check Out Hikal (NSE:HIKAL) Before It's Too Late

Shareholder Returns

HIKALIN PharmaceuticalsIN Market
7D-8.4%1.8%-2.1%
1Y24.5%43.7%22.5%

Return vs Industry: HIKAL underperformed the Indian Pharmaceuticals industry which returned 43.7% over the past year.

Return vs Market: HIKAL exceeded the Indian Market which returned 22.5% over the past year.

Price Volatility

Is HIKAL's price volatile compared to industry and market?
HIKAL volatility
HIKAL Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.1%

Stable Share Price: HIKAL has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: HIKAL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19882,061Sameer Hiremathwww.hikal.com

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredients (APIs).

Hikal Limited Fundamentals Summary

How do Hikal's earnings and revenue compare to its market cap?
HIKAL fundamental statistics
Market cap₹46.71b
Earnings (TTM)₹736.02m
Revenue (TTM)₹18.21b

63.5x

P/E Ratio

2.6x

P/S Ratio

Is HIKAL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HIKAL income statement (TTM)
Revenue₹18.21b
Cost of Revenue₹9.02b
Gross Profit₹9.20b
Other Expenses₹8.46b
Earnings₹736.02m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)5.97
Gross Margin50.50%
Net Profit Margin4.04%
Debt/Equity Ratio64.2%

How did HIKAL perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

10%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 02:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hikal Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. ChavaliFirstCall Research
Siddhant KhandekarICICIdirect.com